SI-BONE (SIBN) Competitors

SI-BONE (NASDAQ:SIBN) and NovoCure (NASDAQ:NVCR) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, media sentiment, community ranking, dividends, valuation and earnings.

Which has more volatility & risk, SIBN or NVCR?

SI-BONE has a beta of 1.17, meaning that its share price is 17% more volatile than the S&P 500. Comparatively, NovoCure has a beta of 0.63, meaning that its share price is 37% less volatile than the S&P 500.

Do analysts prefer SIBN or NVCR?

SI-BONE presently has a consensus target price of $24.50, suggesting a potential upside of 66.10%. NovoCure has a consensus target price of $32.67, suggesting a potential upside of 67.61%. Given NovoCure's higher probable upside, analysts plainly believe NovoCure is more favorable than SI-BONE.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SI-BONE	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	3.00
NovoCure	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.67

Does the media refer more to SIBN or NVCR?

In the previous week, SI-BONE had 1 more articles in the media than NovoCure. MarketBeat recorded 4 mentions for SI-BONE and 3 mentions for NovoCure. NovoCure's average media sentiment score of 1.44 beat SI-BONE's score of 0.54 indicating that NovoCure is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SI-BONE	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
NovoCure	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has higher valuation and earnings, SIBN or NVCR?

SI-BONE has higher earnings, but lower revenue than NovoCure. SI-BONE is trading at a lower price-to-earnings ratio than NovoCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SI-BONE	$167.18M	3.75	-$43.34M	-$0.76	-19.41
NovoCure	$605.22M	3.54	-$207.04M	-$1.56	-12.49

Do institutionals & insiders have more ownership in SIBN or NVCR?

98.1% of SI-BONE shares are owned by institutional investors. Comparatively, 84.6% of NovoCure shares are owned by institutional investors. 3.9% of SI-BONE shares are owned by insiders. Comparatively, 6.3% of NovoCure shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Is SIBN or NVCR more profitable?

SI-BONE has a net margin of -23.82% compared to NovoCure's net margin of -25.93%. SI-BONE's return on equity of -22.51% beat NovoCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SI-BONE	-23.82%	-22.51%	-16.53%
NovoCure	-25.93%	-41.48%	-12.74%

Does the MarketBeat Community prefer SIBN or NVCR?

NovoCure received 305 more outperform votes than SI-BONE when rated by MarketBeat users. However, 68.80% of users gave SI-BONE an outperform vote while only 63.60% of users gave NovoCure an outperform vote.

Company	Underperform	Outperform
SI-BONE	Outperform Votes 172 68.80%	Underperform Votes 78 31.20%
NovoCure	Outperform Votes 477 63.60%	Underperform Votes 273 36.40%

Summary

SI-BONE beats NovoCure on 11 of the 18 factors compared between the two stocks.